Becton, Dickinson and Company $BDX Shares Purchased by Mufg Securities Americas Inc.

Mufg Securities Americas Inc. boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 25.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 6,352 shares of the medical instruments supplier’s stock after purchasing an additional 1,269 shares during the period. Mufg Securities Americas Inc.’s holdings in Becton, Dickinson and Company were worth $1,094,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Evelyn Partners Investment Management Services Ltd raised its holdings in shares of Becton, Dickinson and Company by 147.0% in the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 4,417 shares of the medical instruments supplier’s stock valued at $779,000 after buying an additional 2,629 shares during the period. Evelyn Partners Investment Management LLP boosted its holdings in Becton, Dickinson and Company by 108.3% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 9,335 shares of the medical instruments supplier’s stock valued at $1,608,000 after acquiring an additional 4,854 shares during the period. Evelyn Partners Investment Management Europe Ltd grew its position in Becton, Dickinson and Company by 1,417.9% in the 2nd quarter. Evelyn Partners Investment Management Europe Ltd now owns 1,017 shares of the medical instruments supplier’s stock valued at $175,000 after acquiring an additional 950 shares in the last quarter. Journey Strategic Wealth LLC increased its stake in Becton, Dickinson and Company by 73.8% during the second quarter. Journey Strategic Wealth LLC now owns 2,423 shares of the medical instruments supplier’s stock worth $417,000 after purchasing an additional 1,029 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Becton, Dickinson and Company by 36.8% during the second quarter. Franklin Resources Inc. now owns 2,685,886 shares of the medical instruments supplier’s stock worth $462,644,000 after purchasing an additional 722,793 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,249 shares of company stock valued at $231,358 over the last three months. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.6%

Shares of NYSE:BDX opened at $192.57 on Friday. The company has a market capitalization of $55.20 billion, a PE ratio of 34.63, a P/E/G ratio of 1.42 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The firm has a 50 day simple moving average of $186.83 and a 200-day simple moving average of $182.33.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of research reports. Stifel Nicolaus dropped their price objective on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Argus boosted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Piper Sandler reduced their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Finally, Royal Bank Of Canada reduced their price target on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $203.27.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.